Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients

Status Not yet recruiting

Clinical Trial Summary

This is a prospective, multi-centre, cross sectional observational study to determine the prevalence of ocular surface disease (OSD) in glaucoma patients, nationwide. The study also analyses sub group of OSD prevalence, stratified according to the treatment types (i.e. preserved, preservative-free, and combination of preservative-free and preserved eyedrops), and illustrates the patient perspective on OSD.

Clinical Trial Description

For this prospective, multi-centre, cross sectional observational study, patients who attend routine eye examination at the medical institutions and who have been diagnosed with primary open-angle glaucoma, primary angle-closure glaucoma, pseudoexfoliation glaucoma, pigment dispersion glaucoma or ocular hypertension will be studied. The medical institutions are selected across different regions of Malaysia to assess the nationwide prevalence of OSD in glaucoma patients. The routine assessments include Corneal Evaluation, Tear Break-Up Time (TBUT), Hyperemia and Schirmer's test whereby the data from these assessments will be collected and analyzed. The study will also includes Symptom Evaluation and Questionnaire feedback. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04609345
Study type	Observational
Source	Santen Pharma Malaysia Sdn Bhd
Contact	Dr. Gan
Phone	603-22848989
Email	ganenghui@yahoo.com.my
Status	Not yet recruiting
Phase
Start date	November 2020
Completion date	May 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03284853` - Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension	Phase 3
Completed	`NCT01157364` - Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension	Phase 1/Phase 2
Not yet recruiting	`NCT06441643` - Next Generation Rocklatan	Phase 2
Recruiting	`NCT02471105` - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml	Phase 4
Recruiting	`NCT02792803` - A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma	Phase 4
Terminated	`NCT02801617` - Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension	Phase 3
Completed	`NCT02558374` - Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension	Phase 3
Completed	`NCT02390245` - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study	N/A
Completed	`NCT02338362` - Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma	Phase 4
Completed	`NCT02993445` - Effect of Alternate Therapies on Intraocular Pressure in Ocular Hypertension	N/A
Completed	`NCT02628223` - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma	N/A
Completed	`NCT02246764` - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension	Phase 3
Completed	`NCT02003547` - A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects	Phase 1
Completed	`NCT01995136` - Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma	Phase 4
Completed	`NCT01936389` - A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma	Phase 2
Completed	`NCT01693315` - Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma	Phase 2
Completed	`NCT01664039` - An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®	Phase 4
Active, not recruiting	`NCT01430923` - Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost	N/A
Completed	`NCT01426867` - A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%	Phase 2
Completed	`NCT01489670` - Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension	N/A